Plant-derived compounds as potential neuroprotective agents in Parkinson's disease

IF 3.2 3区医学 Q2 NUTRITION & DIETETICS

Nutrition Pub Date : 2024-10-23 DOI:10.1016/j.nut.2024.112610

Chengu Niu M.D. , Yu Zou M.Sc. , Miaoxian Dong M.B.B.S. , Yingcai Niu Ph.D.

{"title":"Plant-derived compounds as potential neuroprotective agents in Parkinson's disease","authors":"Chengu Niu M.D. , Yu Zou M.Sc. , Miaoxian Dong M.B.B.S. , Yingcai Niu Ph.D.","doi":"10.1016/j.nut.2024.112610","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>Current Parkinson's disease (PD) medications treat symptoms; none can slow down or arrest the disease progression. Disease-modifying therapies for PD remain an urgent unmet clinical need. This review was designed to summarize recent findings regarding to the efficacy of phytochemicals in the treatment of PD and their underlying mechanisms.</div></div><div><h3>Methods</h3><div>A literature search was performed using PubMed databases from inception until January 2024.</div></div><div><h3>Results</h3><div>We first review the role of oxidative stress in PD and phytochemical-based antioxidant therapy. We then summarize recent work on neuroinflammation in the pathogenesis of PD, as well as preclinical data supporting anti-inflammatory efficacy in treating or preventing the disease. We last evaluate evidence for brain mitochondrial dysfunction in PD, together with the phytochemicals that protect mitochondrial function in preclinical model of PD. Furthermore, we discussed possible reasons for failures of preclinical-to-clinical translation for neuroprotective therapeutics.</div></div><div><h3>Conclusions</h3><div>There is now extensive evidence from preclinical studies that neuroprotective phytochemicals as promising candidate drugs for PD are needed to translate from the laboratory to the clinic.</div></div>","PeriodicalId":19482,"journal":{"name":"Nutrition","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nutrition","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0899900724002594","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives

Current Parkinson's disease (PD) medications treat symptoms; none can slow down or arrest the disease progression. Disease-modifying therapies for PD remain an urgent unmet clinical need. This review was designed to summarize recent findings regarding to the efficacy of phytochemicals in the treatment of PD and their underlying mechanisms.

Methods

A literature search was performed using PubMed databases from inception until January 2024.

Results

We first review the role of oxidative stress in PD and phytochemical-based antioxidant therapy. We then summarize recent work on neuroinflammation in the pathogenesis of PD, as well as preclinical data supporting anti-inflammatory efficacy in treating or preventing the disease. We last evaluate evidence for brain mitochondrial dysfunction in PD, together with the phytochemicals that protect mitochondrial function in preclinical model of PD. Furthermore, we discussed possible reasons for failures of preclinical-to-clinical translation for neuroprotective therapeutics.

Conclusions

There is now extensive evidence from preclinical studies that neuroprotective phytochemicals as promising candidate drugs for PD are needed to translate from the laboratory to the clinic.

查看原文本刊更多论文

作为帕金森病潜在神经保护剂的植物提取物。

目标：目前的帕金森病（PD）药物只能治疗症状，无法减缓或阻止疾病进展。帕金森病的疾病调节疗法仍是一项尚未得到满足的迫切临床需求。本综述旨在总结有关植物化学物质治疗帕金森病的疗效及其内在机制的最新发现：方法：使用 PubMed 数据库对从开始到 2024 年 1 月的文献进行了检索：我们首先回顾了氧化应激在帕金森病中的作用以及基于植物化学物质的抗氧化疗法。然后，我们总结了神经炎症在帕金森病发病机制中的最新研究成果，以及支持抗炎治疗或预防该疾病疗效的临床前数据。最后，我们评估了帕金森病脑线粒体功能障碍的证据，以及在帕金森病临床前模型中保护线粒体功能的植物化学物质。此外，我们还讨论了神经保护疗法从临床前到临床转化失败的可能原因：目前临床前研究的大量证据表明，神经保护性植物化学物质作为治疗帕金森病的有前途的候选药物，需要从实验室转化到临床。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nutrition 医学-营养学

CiteScore

7.80

自引率

2.30%

发文量

300

审稿时长

60 days

期刊介绍： Nutrition has an open access mirror journal Nutrition: X, sharing the same aims and scope, editorial team, submission system and rigorous peer review. Founded by Michael M. Meguid in the early 1980''s, Nutrition presents advances in nutrition research and science, informs its readers on new and advancing technologies and data in clinical nutrition practice, encourages the application of outcomes research and meta-analyses to problems in patient-related nutrition; and seeks to help clarify and set the research, policy and practice agenda for nutrition science to enhance human well-being in the years ahead.